Barclays’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Barclays’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Hold	0	–	–	–	5275
2020 Q3	–	Hold	0	–	–	–	5800
2020 Q2	–	Hold	0	–	–	–	6509
2020 Q1	–	Sell	-148	Closed	-$45.3K	–	6665
2019 Q4	$49K	Sell	148 -31	-17%	-$14.2K	﹤0.01%	5748
2019 Q3	$89K	Buy	+179	New	+$101K	﹤0.01%	5569
2019 Q2	–	Hold	0	–	–	–	7480
2019 Q1	–	Sell	-1	Closed	-$545	–	7501
2018 Q4	$0	Sell	1 -18	-95%	-$9.68K	﹤0.01%	7586
2018 Q3	$13K	Buy	19 +2	+12%	+$1.42K	﹤0.01%	6599
2018 Q2	$15K	Sell	17 -8	-32%	-$9.16K	﹤0.01%	6356
2018 Q1	$31K	Sell	25 -9	-26%	-$13.3K	﹤0.01%	6234
2017 Q4	$51K	Buy	+34	New	+$53.8K	﹤0.01%	5751

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Barclays's NBRV Position: Q4 2020 in Review

Barclays held its Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) position steady in Q4 2020 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5275.

Barclays first reported a position in NBRV in Q4 2017 and has held it in 7 quarters since. The position peaked at $89K in Q3 2019. 33 funds tracked by Wall St. Rank hold NBRV as of Q4 2020.

Barclays held 0 shares of Nabriva Therapeutics plc Ordinary Shares Ireland worth $0 as of Q4 2020.
Barclays left its Nabriva Therapeutics plc Ordinary Shares Ireland share count unchanged in Q4 2020.
Nabriva Therapeutics plc Ordinary Shares Ireland made up ﹤0.01% of Barclays's portfolio in Q4 2020, its #5275 holding.
Barclays first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2017 and has held it in 7 quarters since.
Barclays's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $89K in Q3 2019.
33 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2020.

Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.